epigallocatechin gallate has been researched along with Chronic Hepatitis C in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Darwish, NHE; Elbasiony, M; Mousa, SA; Shiha, G; Soliman, R | 1 |
| Daskalakis, C; Halegoua-De Marzio, D; Hawke, RL; Kraft, WK; Navarro, VJ; Ying, X | 1 |
2 trial(s) available for epigallocatechin gallate and Chronic Hepatitis C
| Article | Year |
|---|---|
Addition of Epigallocatechin Gallate 400 mg to Sofosbuvir 400 mg + Daclatisvir 60 mg With or Without Ribavirin in Treatment of Patients with Chronic Hepatitis C Improves the Safety Profile: A Pilot Study.
Topics: Adult; Catechin; Daclizumab; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Pilot Projects; Random Allocation; Ribavirin; Sofosbuvir; Standard of Care; Sustained Virologic Response; Tablets; Treatment Outcome; Viral Load | 2019 |
Limited sampling estimates of epigallocatechin gallate exposures in cirrhotic and noncirrhotic patients with hepatitis C after single oral doses of green tea extract.
Topics: Administration, Oral; Aged; Antioxidants; Area Under Curve; Catechin; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Plant Extracts; Tea; Time Factors | 2012 |